Follow the Whitehawk Therapeutics, Inc. share price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares are listed on the US market, under the authority of SEC (Form 4). Market capitalisation: €2.5bn. The latest transaction was filed on 30 July 2026 (Attribution). Among the most active insiders: Lennon David James. All data is accessible without an account.
18
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
€2m
11 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Whitehawk Therapeutics, Inc. Strong Buy (bullish), based on 12 analysts. Average price target: US$62.05.
38Σ signal
Buys n/a€2m Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
Whitehawk Therapeutics, Inc. es una empresa biofarmacéutica centrada en el desarrollo de tratamientos para enfermedades autoinmunes. Emplea enfoques innovadores para atacar los mecanismos subyacentes de estas afecciones.